Palliative Radiotherapy for Painful Bone Metastases in a Patient with Poor Performance Status
A 68-year-old man with metastatic castration-resistant prostate cancer has multiple blastic bone metastases involving the thoracic spine, ribs, and pelvis. He has severe lower back pain (7/10) requiring escalating opioids, with functional decline over the past month. ECOG performance status is 3. He has no evidence of spinal cord compression on MRI, and no pathologic fracture. He lives 90 minutes from the cancer center and has limited transportation. He is currently on docetaxel but has had two dose reductions for fatigue. He asks about radiation for the pain.
1. What radiotherapy approach would you recommend, and why?
Read the worked answer
For uncomplicated painful bone metastases (no cord compression, no fracture), single-fraction radiotherapy (8 Gy) is a standard option with efficacy comparable to multifraction regimens (e.g., 30 Gy in 10 fractions) for pain relief, albeit with a slightly higher rate of retreatment. Given his ECOG 3 status and 90-minute travel distance, single-fraction treatment minimizes burden and is the pragmatic choice.
Important considerations:
- His poor performance status and functional decline raise the question of whether he is near end of life; if prognosis is short, minimizing treatment burden is paramount.
- He has multiple painful sites; treating all of them with separate courses may be impractical. Prioritize the most symptomatic site (thoracic spine) and consider whether a single treatment field can cover adjacent symptomatic areas.
- Docetaxel may be contributing to fatigue; coordination with medical oncology about holding or stopping chemotherapy is reasonable, since concurrent chemotherapy and radiotherapy can worsen myelosuppression and fatigue.
The judgment: single-fraction radiotherapy is appropriate and preferable here, but the broader question is goals of care - the radiation plan should be integrated into a palliative plan, not delivered in isolation.
2. What would you assess before delivering radiotherapy, and what complications would you specifically counsel about?
Read the worked answer
Pre-treatment assessment:
- Confirm the painful site correlates with imaging - in a patient with multiple blastic lesions, the pain generator is not always obvious. A bone scan or MRI can help localize.
- Assess for cord compression or impending fracture at the treated site, since these change the treatment (surgical consultation, steroids, or altered fields).
- Review blood counts, especially if he is on docetaxel, to assess marrow reserve; a single fraction to the thoracic spine has minimal marrow impact, but multiple fields do not.
- Assess renal function if considering bone-modifying agents (zoledronic acid) concurrently.
- Discuss goals of care and prognosis.
Counseling:
- Pain flare occurs in a subset of patients in the days after treatment; a short course of corticosteroids or NSAIDs can mitigate it, and patients should be warned so they do not interpret it as treatment failure.
- Fatigue is common and may be compounded by docetaxel.
- Skin reaction is usually mild with single fraction.
- There is a small risk of myelosuppression if a large marrow volume is treated.
- Retreatment is possible if pain recurs, which is why single fraction is acceptable.
The judgment point is that pain flare counseling and confirmation of the pain generator are as important as the prescription itself.